Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment

to related objects

We present a case of severe bowel perforation during lenvatinib treatment for advanced hepatocellular carcinoma. Although the Hartmann’s procedure was performed, the patient died 48 h after the operation. The histopathological findings suggested that lenvatinib was involved in the etiology of bowel perforation in this case.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment ; volume:16 ; number:2 ; year:2022 ; pages:502-506 ; extent:5
Case reports in gastroenterology ; 16, Heft 2 (2022), 502-506 (gesamt 5)

Creator
Mizokami, Ken
Watanabe, Akiko
Yamaguchi, Eriko
Saito, Akira

DOI
10.1159/000525569
URN
urn:nbn:de:101:1-2022092200560520011552
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Mizokami, Ken
  • Watanabe, Akiko
  • Yamaguchi, Eriko
  • Saito, Akira

Other Objects (12)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma

Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma

Related objects